Patient factors that influence warfarin dose response

Journal of Pharmacy Practice

Volumn 23, Issue 3, 2010, Pages 194-204

  White, Pamela J ^a  

^a Legacy Health Anticoagulation Clinics   (United States)

Author keywords

Anticoagulation; Bleeding risk; INR; Vitamin K antagonists; Warfarin

Indexed keywords

AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; AZITHROMYCIN; BARBITURIC ACID DERIVATIVE; BOSENTAN; CARBAMAZEPINE; CELECOXIB; CHLORDIAZEPOXIDE; CIMETIDINE; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; COLESTYRAMINE; DICLOXACILLIN; DRONEDARONE; ERYTHROMYCIN; FENOFIBRATE; FISH OIL; FLUCONAZOLE; FLUINDOSTATIN; FLUOROURACIL; GRISEOFULVIN; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; THIAMAZOLE; TRAMADOL; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; ETHNICITY; GENETIC VARIABILITY; GRAVES DISEASE; GROUPS BY AGE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIVER DISEASE; LUNG FIBROSIS; NUTRITIONAL STATUS; ORTHOPEDIC SURGERY; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID DISEASE;

EID: 77953832620     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010362177     Document Type: Review

References (130)

1. Gulseth MP, Michaud J., Nutescu EA Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008 ; 65 (16). 1520-1529.
2. Carreiro J., Ansell J. Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs. 2008 ; 17 (12). 1937-1945.
3. Hass S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008 ; 25 (1). 52-60.
4. Hirsh J., ODonnell M., Eikelboom J. Beyond unfractionated heparin and warfarin. Circulation. 2007 ; 116 (5). 552-560.
5. Gross P., Weitz J. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008 ; 28 (3). 380-386.
6. Bates SM, Greer IA, Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2008 ; 133 (6 suppl). 844S - 886S.
7. Bonow RO, Carabello BA, Chatterjee K., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force. J Am Coll Cardiol. 2008 ; 52 (13). e1 - e142.
8. Garcia D., Regan S., Crowther M., et al. Warfarin maintenance dosing patterns in clinical practice. Chest. 2005 ; 127 (6). 2049-2056.
9. Crowther MA, Ginsberg JB, Kearon C., et al. A randomized trial comparing 5 mg and 10 mg warfarin loading doses. Arch Intern Med. 1999 ; 159 (1). 46-48.
10. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992 ; 45 (8). 704-706.
11. Gurwitz JH, Avorn J., Ross-Degnan D., et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992 ; 116 (11). 901-904.
12. Singla DA, Morrill GB Warfarin maintenance dosages in the very elderly. Am J Health Syst Pharm. 2005 ; 62 (10). 1062-1066.
13. Hylek EM Oral anticoagulants pharmacologic issues for use in elderly. Clin Geriatr Med. 2001 ; 17 (1). 1-13.
14. Chan E., McLachlan AJ, Pegg M., et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol. 1994 ; 37 (6). 563-569.
15. Routeldge PA, Chapman PH, Davies DM, et al. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol. 1979 ; 8: 243-247.
16. Shepherd AM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977 ; 4 (3). 315-320.
17. Siguret V., Gouin I., Debray M., et al. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am J Med. 2005 ; 118 (2). 137-142. (Pubitemid 40202860)
18. OConnell MB, Kowal PR, Allivato CJ, et al. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy. 2000 ; 20 (8). 923-930.
19. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008 ; 133 (6 suppl). 160S - 198S.
20. Absher RK, Moore ME, Parker MH Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002 ; 36 (10). 1512-1517.
21. Whitely HP, Fermo JD, Chumney EC, et al. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag. 2007 ; 3 (3). 499-504.
22. Cushman M., Booth SL, Possidente CL, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol. 2001 ; 112 (3). 572-577.
23. Couris RR, Tataronis GR, Booth SL, et al. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr. 2000 ; 19 (6). 801-806.
24. Couris R., Tataronis G., McCloskey W., et al. Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. Int J Vitam Nutr Res. 2006 ; 76 (2). 65-74.
25. Franco V., Polanczyk CA, Clausell N., et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004 ; 116 (10). 651-656.
26. Kurnick D., Loebstein R., Rabinovitz H., et al. Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. Thromb Haemost. 2004 ; 92 (5). 1018-1024.
27. Sconce E., Avery P., Wynne H., et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007 ; 109 (6). 2419-2423.
28. Reese AM, Farnett LE, Lyons R., et al. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy. 2005 ; 25 (12). 1746-1751.
29. Ford SK, Misita CP, Shilliday BB, et al. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis. 2007 ; 24 (1). 23-27.
30. Beatty SJ, Mehta BM, Rodis JL Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother. 2005 ; 39 (4). 744-747.
31. Hornsby LB, Hester EK, Donaldson AR Potential interaction between warfarin and high dietary protein intake. Pharmacotherapy. 2008 ; 28 (4). 536-539.
32. Gallus AS, Lucas CR, Hirsh J. Coagulation studies in patients with acute infectious hepatitis. Br J Haematol. 1972 ; 22 (6). 761-771.
33. Deitcher SR Interpretation of the international normalised ratio in patients with liver disease. Lancet. 2002 ; 359 (9300). 47-48.
34. Kovacs MJ, Wong A., MacKinnon K., et al. Assessment of the variability of the INR system for patients with liver impairment. Thromb Haemost. 1994 ; 71 (6). 727-730.
35. Kujovich JL Hemostatic defects in end stage liver disease. Crit Care Clin. 2005 ; 21 (3). 563-587.
36. Blanchard RA, Furie BC, Jorgensen M., et al. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med. 1981 ; 305 (5). 242-248.
37. The Joint Commission. 2009 National Patient Safety Goals. The Joint Commission Web site. October 31, 2008. http://www.jointcommission.org/ PatientSafety/NationalPatientSafetyGoals/09-hap-npsgs.htm. Accessed June 20, 2009.
38. Brigden ML, Kay C., Le A., et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol. 1998 ; 59 (1). 22-27.
39. Zhang K., Young C., Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm. 2006 ; 12 (8). 640-648.
40. Landefeld CS, Goldman OL Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989 ; 87 (2). 144-152.
41. Beyth RJ, Quinn LM, Landefeld CS Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998 ; 105 (2). 91-99.
42. DiMarco JP, Flaker G., Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the AFFIRM study. Am Heart J. 2005 ; 149 (4). 650-656.
43. Elliott MJ, Zimmerman D., Holden RM Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007 ; 50 (3). 433-440.
44. Holden RM, Harman GJ, Wang M., et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol. 2008 ; 3 (1). 105-110.
45. Chan KE, Lazarus JM, Thadhani R., et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009 ; 20 (4). 872-881.
46. Limdi NA, Beasley M., Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009 ; 20 (4). 912-921.
47. Pichette V., Leblond FA Drug metabolism in chronic renal failure. Curr Drug Metab. 2003 ; 4 (2). 91-103.
48. Dreisbach AW, Japa S., Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003 ; 73 (5). 475-477.
49. OConnor P., Feely J. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin Pharmacokinet. 1987 ; 13 (6). 345-364.
50. Demirkan K., Stephens MA, Newman KP, et al. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J. 2000 ; 93 (5). 448-454. (Pubitemid 30366220)
51. Chute JP, Ryan CP, Sladek G., et al. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr Pract. 1997 ; 3 (2). 77-79.
52. Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med. 1986 ; 58 (225). 43-51.
53. Akin F., Yaylali GF, Bastemir M., et al. Effect of methimazole on warfarin anticoagulation in a case of Graves disease. Blood Coagul Fibrinolysis. 2008 ; 19 (1). 89-91.
54. Busenbark LA, Cushnie SA Effect of Graves disease and methimazole on warfarin anticoagulation. Ann Pharmacother. 2006 ; 40 (6). 1200-1203.
55. Stephens MA, Self TH, Lancaster D., et al. Hypothyroidism: effect on warfarin anticoagulation. South Med J. 1989 ; 82 (12). 1585-1586.
56. Bucerius J., Joe AY, Palmedo H., et al. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid. 2006 ; 16 (4). 369-374.
57. Zimetbaum P., Ho KK, Olshansky B., et al. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol. 2003 ; 91 (1). 81-83. (Pubitemid 36050777)
58. Doyle JF, Ho KM Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc. 2009 ; 84 (3). 234-242.
59. Heimark LD, Wienkers L., Kunze K., et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992 ; 51 (4). 398-407.
60. Sanoski CA, Bauman JL Clinical observations with the amiodarone/warfarin interaction. Chest. 2002 ; 121 (1). 19-23.
61. Lu Y., Won KA, Nelson BJ, et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health-Syst Pharm. 2008 ; 65 (10). 947-952.
62. Harjai KJ, Licata AA Effects of amiodarone on thyroid function. Ann Intern Med. 1997 ; 126 (1). 63-73.
63. Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007 ; 120 (10). 880-885.
64. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007 ; 356 (9). 935-941.
65. Patel C., Yan GX, Kowey PR Dronedarone. Circulation. 2009 ; 120 (7). 636-644.
66. Garcia D., Cheng-Lai A. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation. Cardiol Rev. 2009 ; 17 (5). 230-234.
67. Hohnloser SH, Crijns HJ, van Eickels M., et al. Effect for dronedarone on cardiovascular events in atrial fibrillation. N Eng J Med. 2009 ; 360 (7). 668-678.
68. Davy JM, Herold M., Hoglund C., et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008 ; 156 (3). 527.e1-527.e9.
69. Self TH, Reaves AB, Oliphant SC, et al. Does heart failure exacerbation increase response to warfarin? A critical review of the literature. Curr Med Res Opin. 2006 ; 22 (11). 2089-2094.
70. Oates LE, Jackson PR, Austin CA, et al. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol. 1998 ; 46 (2). 157-161.
71. Graham SP Anticoagulation and Heart Failure. Curr Cardiol Rep. 2001 ; 3 (1). 72-77.
72. Visser LE, Bleumink GS, Trienekens PH, et al. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004 ; 127 (1). 85-89.
73. Witt DM, Delate W., Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009 ; 114 (5). 952-956.
74. Penning-van Beest FJ, van Meegen E., Rosendaal FR Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost. 2001 ; 86 (2). 569-574.
75. Cadiou G., Varin R., Levesque H., et al. Risk factors of vitamin K antagonist overanticoagulation: a case-control study in unselected patients referred to an emergency department. Thromb Haemost. 2008 ; 100 (4). 685-692.
76. Schulman S., El Bouazzaoui B., Eikelboom JW, et al. Clinical factors influencing the sensitivity to warfarin when restarted after surgery. J Intern Med. 2008 ; 263 (4). 412-419.
77. Rahman M., BinEsmael TM, Payne N., et al. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother. 2006 ; 40 (3). 397-401.
78. Ageno W., Turpie AGG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol. 1999 ; 84 (8). 905-908.
79. Lee J., Lee B., Kim K., et al. Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother. 2002 ; 36 (12). 1845-1850.
80. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 ; 56 (5). 824-834.
81. Chandler WL Effect of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2005 ; 19 (4). 459-467.
82. Ageno W., Turpie AGG, Steidl L., et al. Comparison of a daily fixed 2.5mg warfarin dose with a 5mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol. 2001 ; 88 (1). 40-44.
83. Meijer K., Kim YK, Schulman S. Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing. Thromb Res. Epub 30 Mar 2009 ; DOI:10.1016/ j.thromres.2009.02.012.
84. Lenzini PA, Grice GR, Milligan PE, et al. Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother. 2007 ; 41 (11). 1798-1804.
85. Lemaire R. Strategies for blood management in orthopaedic and trauma surgery. J Bone Joint Surg (Br). 2008 ; 90-B (9). 1128-1136.
86. Snaith A., Pugh L., Simpson CR, et al. The potential for interaction between warfarin and coprescribed medication. Am J Cardiovasc Drugs. 2008 ; 8 (3). 207-212.
87. Verhovsek M., Motlagh B., Crowther MA, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatrics. 2008 ; 8: 13.
88. Howard PA, Ellerbeck EF, Engelman KK, et al. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmcoepidemiol Drug Safe. 2002 ; 11 (7). 569-576.
89. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007 ; 120 (6). 539-544.
90. Malone DC, Hutchins DS, Haupert H., et al. Assessment of potential drug-drug interations with a prescription claims database. Am J Health Syst Pharm. 2005 ; 62 (19). 1983-1991.
91. Glassman PA, Simon B., Belperio P., et al. Improving recognition of drug interactions: benefits and barriers to using automatic drug alerts. Med Care. 2002 ; 40 (12). 1161-1171.
92. Weideman RA, Bernstein IH, McKinney WP Pharmacist recognition of potential drug interactions. Am J Health-Syst Pharm. 1999 ; 56 (15). 1524-1529.
93. Anthony M., Romero K., Malone DC, et al. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther. 2009 ; 86 (4). 425-429.
94. Holbrook AM, Pereria JA, Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 ; 165 (10). 1095-1106.
95. Abarca J., Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004 ; 44 (2). 136-141.
96. Feldstein AC, Smith DH, Perrin N., et al. Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med. 2006 ; 166 (9). 1009-1015.
97. Heck AM, DeWitt BA, Lukes AL Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000 ; 57 (13). 1221-1227.
98. Leung VW, Shalansky SJ, Lo MK, et al. Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmacother. 2009 ; 43 (5). 875-881.
99. Shalansky S., Lynd L., Richardson K., et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longtitudinal analysis. Pharmacotherapy. 2007 ; 27 (9). 1237-1247.
100. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003 ; 348 (6). 529-537.
101. Evans WE, McLeod HL Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003 ; 348 (6). 538-549.
102. Wilkinson GR Drug metabolism and variability among patients in drug response. N Engl J Med. 2005 ; 352 (21). 2211-2221.
103. Huang SM, Goodsaid F., Rahman A., et al. Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods. 2006 ; 16 (2-3). 89-99.
104. Bristol Myers Squibb. Coumadin Label approved 08/16/07. Drugs@FDA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/009218s105lblv2.pdf. Accessed July 23, 2009.
105. Gage BF, Lesko LJ Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008 ; 25 (1). 45-51.
106. Wadelius M., Chen LY, Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005 ; 5 (4). 262-270.
107. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 ; 106 (7). 2329-2333.
108. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353 (9168). 717-719.
109. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 287 (13). 1690-1698.
110. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000 ; 96 (5). 1816-1819.
111. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 ; 352 (22). 2285-2293.
112. Zhu Y., Shennan M., Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007 ; 53 (7). 1199-1205.
113. Loebstein R., Dvoskin I., Halkin H., et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007 ; 109 (6). 2477-2480.
114. DAndrea G., DAmbrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 ; 105 (2). 645-649.
115. Tham LS, Goh BC, Nafziger A., et al. A warfarin-dosing model in asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006 ; 80 (4). 346-355.
116. Gage BF, Eby C., Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ; 84 (3). 326-331.
117. Schelleman H., Chen J., Chen Z., et al. Dosing algorithms to predict warfarin maintenance dose in caucasians and african americans. Clin Pharmacol Ther. 2008 ; 84 (3). 332-339.
118. Klein TE, Altman RB, Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Eng J Med. 2009 ; 360 (8). 753-764.
119. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost. 2008 ; 6 (10). 1655-1662.
120. Garcia DA, Hylek E. Warfarin pharmacogenetics. N Engl J Med. 2009 ; 360 (23). 2474.
121. Bussey HI, Wittkowsky AK, Hylek EM, et al. Genetic testing for warfarin? Not yet ready for prime time. Pharmacotherapy. 2008 ; 28 (2). 141-143.
122. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116 (22). 2563-2570.
123. Eckman MH, Rosand J., Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009 ; 150 (2). 73-83.
124. Centers for Medicare and Medicaid Services Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400n). HHS.gov. 2009. https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo. asp&id=224&. Accessed August 22, 2009.
125. National Heart, Lung, and Blood Institute. Clarification of optimal anticoagulation through genetics (COAG). Clinical Trials.gov. http://clinicaltrials.gov/ct2/show/NCT00839657. Accessed August 7, 2009.
126. Dang MT, Hambleton J., Kayser SR The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005 ; 39 (6). 1008-1112.
127. Gulseth MP, Grice GR, Dager WE Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009 ; 66 (2). 123-133.
128. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008 ; 9 (10). 1445-1458.
129. Schwartz UI, Ritchie MD, Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 ; 358 (10). 999-1008.
130. Marsh S., King CR, Porche-Sorbet RM, et al. Population variation in VKORC1 haplotype structure. J Thromb Haemost. 2006 ; 4 (2). 473-474.